Organogenesis
ORGO Healthcare Drug Manufacturers Specialty & Generic
Organogenesis' revenue for fiscal 2025 (year ended December 2025) was $564.2 million, up 17.0% from fiscal 2024. In the quarter to June 2026, revenue fell 56.7%, EPS fell 670.0%, free cash flow grew 10.3% and total debt rose 10,940.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow ORGO
Organogenesis (ORGO) Altman Z-score
Organogenesis's Altman Z-score for fiscal 2025 is 3.03, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 3.03 | 0.60 |
| FY2024 | 2.43 | (0.63) |
| FY2023 | 3.06 | 0.50 |
| FY2022 | 2.56 | (2.75) |
| FY2021 | 5.31 | 0.87 |
| FY2020 | 4.44 | 2.81 |
| FY2019 | 1.63 | (1.13) |
| FY2018 | 2.76 | (0.24) |
| FY2017 | 3.00 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.44 | — | 0.53 | |
| Retained earnings / total assets | (0.01) | — | −0.01 | |
| EBIT / total assets | 0.07 | — | 0.25 | |
| Market value of equity / total liabilities | 2.20 | — | 1.32 | |
| Sales / total assets | 0.94 | — | 0.94 | |
| Altman Z-score | Safe zone | 3.03 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 4.41 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| BGM BGM Group Ltd. compare | 498× |
| CRDL Cardiol Therapeutics Inc. compare | 3.4× |
| ORGO Organogenesis | 3.0× |
| DERM Journey Medical Corporation compare | 1.1× |
| CPIX Cumberland Pharmaceuticals Inc. compare | 0.7× |
| OGI Organigram Global Inc. compare | 0.2× |
| PROCF Sofgen Pharma S.A compare | −1.4× |
| AKBA Akebia Therapeutics, Inc. compare | −4.4× |
| CLVR Clever Leaves Holdings Inc. compare | −9.4× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets